385 related articles for article (PubMed ID: 30940295)
1. Different Types of
He Y; Sheng W; Hu W; Lin J; Liu J; Yu B; Mao X; Zhang L; Huang J; Wang G
Oncol Res; 2019 Aug; 27(8):901-910. PubMed ID: 30940295
[No Abstract] [Full Text] [Related]
2. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Xu H; Zhang Q; Liang L; Li J; Liu Z; Li W; Yang L; Yang G; Xu F; Ying J; Zhang S; Wang Y
Cancer Med; 2020 May; 9(10):3328-3336. PubMed ID: 32168429
[TBL] [Abstract][Full Text] [Related]
4. Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.
Cui M; Han Y; Li P; Zhang J; Ou Q; Tong X; Zhao R; Dong N; Wu X; Li W; Jiang G
Mol Oncol; 2020 Nov; 14(11):2787-2795. PubMed ID: 32871626
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ
J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.
Zhang L; Jiang T; Zhao C; Li W; Li X; Zhao S; Liu X; Jia Y; Yang H; Ren S; Zhou C
Oncotarget; 2016 Nov; 7(46):75145-75154. PubMed ID: 27738334
[TBL] [Abstract][Full Text] [Related]
7. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
Moro-Sibilot D; Cozic N; Pérol M; Mazières J; Otto J; Souquet PJ; Bahleda R; Wislez M; Zalcman G; Guibert SD; Barlési F; Mennecier B; Monnet I; Sabatier R; Bota S; Dubos C; Verriele V; Haddad V; Ferretti G; Cortot A; De Fraipont F; Jimenez M; Hoog-Labouret N; Vassal G
Ann Oncol; 2019 Dec; 30(12):1985-1991. PubMed ID: 31584608
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Shaw AT; Ou SH; Bang YJ; Camidge DR; Solomon BJ; Salgia R; Riely GJ; Varella-Garcia M; Shapiro GI; Costa DB; Doebele RC; Le LP; Zheng Z; Tan W; Stephenson P; Shreeve SM; Tye LM; Christensen JG; Wilner KD; Clark JW; Iafrate AJ
N Engl J Med; 2014 Nov; 371(21):1963-71. PubMed ID: 25264305
[TBL] [Abstract][Full Text] [Related]
9. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.
Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S
Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
12. ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
[TBL] [Abstract][Full Text] [Related]
13. CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations.
Li W; Fei K; Guo L; Wang Y; Shu C; Wang J; Ying J
J Thorac Oncol; 2024 Apr; 19(4):613-625. PubMed ID: 38070598
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
Zhang Y; Zhang X; Zhang R; Xu Q; Yang H; Lizaso A; Xu C; Liu J; Wang W; Ou SI; Zhang J; Song Z; Yang N
BMC Med; 2021 Sep; 19(1):206. PubMed ID: 34511132
[TBL] [Abstract][Full Text] [Related]
15. Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.
Dudnik E; Agbarya A; Grinberg R; Cyjon A; Bar J; Moskovitz M; Peled N;
Clin Transl Oncol; 2020 Dec; 22(12):2303-2311. PubMed ID: 32462394
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.
Liu C; Yu H; Chang J; Chen H; Li Y; Zhao W; Zhao K; Zhu Z; Sun S; Fan M; Wang J
Target Oncol; 2019 Jun; 14(3):315-323. PubMed ID: 30976989
[TBL] [Abstract][Full Text] [Related]
18. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
[TBL] [Abstract][Full Text] [Related]
19. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
[TBL] [Abstract][Full Text] [Related]
20. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]